Inqovi (decitabine/cedazuridine) / Otsuka  >>  Phase 2
Welcome,         Profile    Billing    Logout  

38 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Inqovi (decitabine/cedazuridine) / Otsuka
2020-004772-18: A Study of the Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination with Venetoclax in AML Estudio de la farmacocinética, la seguridad y la eficacia de ASTX727 en combinación con venetoclax en casos de LMA

Not yet recruiting
2
100
Europe
ASTX727 (decitabine and cedazuridine), Venetoclax, ASTX727, Tablet, Film-coated tablet, Venclyxto
Astex Pharmaceuticals, Inc., Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia (AML) Leucemia mieloide aguda (LMA), Acute Myeloid Leukemia (AML) Leucemia mieloide aguda (LMA), Diseases [C] - Cancer [C04]
 
 
ASTX727-10, NCT05835011: A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Terminated
2
100
US
Decitabine/Cedazuridine, ASTX727, INQOVI, Magrolimab, Hu5F9-G4
Astex Pharmaceuticals, Inc.
Myelodysplastic Syndromes
08/23
08/23
ETCTN, NCT04340843: Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Active, not recruiting
2
32
US
Belinostat, Beleodaq, PXD 101, PXD101, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Decitabine and Cedazuridine, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inqovi, Guadecitabine, DNMT inhibitor SGI-110, S110, SGI-110, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
01/25
01/25
STIMULUS MDS-US, NCT04878432: : Sabatolimab Added to HMA in Higher Risk MDS

Active, not recruiting
2
39
US
MBG453, sabatolimab, Azacitidine, Decitabine, INQOVI (oral decitabine)
Novartis Pharmaceuticals
Myelodysplastic Syndrome (MDS)
09/23
06/24
NCT06351306: DEC-C and Thioguanine for R/R AML

Recruiting
2
48
US
Thioguanine (Tabloid ®), DecitabineCedazuridine (Inqovi ®)
Joseph Jurcic
Acute Myeloid Leukemia
12/27
12/27
GFM-DACORAL-DLI, NCT04857645 / 2019-003685-40: ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

Active, not recruiting
2
57
Europe
ASTX727, Donor Lymphocyte Infusions, DLI
Groupe Francophone des Myelodysplasies, Astex Pharmaceuticals, Inc.
MDS, AML
04/24
04/25
NCT06297629: A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Not yet recruiting
2
65
US
ASTX727, Inqovi, Donor Lymphocyte Infusion, DLI
M.D. Anderson Cancer Center, Astex Pharmaceuticals, Inc.
Allogeneic Stem Cell Transplantation
08/24
08/26
NCT04746235: Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

Recruiting
2
40
US
Decitabine and Cedazuridine, ASTX727, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, Inqovi, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
10/24
10/24
NCT05007873: ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Recruiting
2
70
US
Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Decitabine and Cedazuridine, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inqovi
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Astex Pharmaceuticals, Inc.
Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, BCR-ABL1 Positive
10/24
10/24
ASTX727-06, NCT04093570 / 2018-003942-18: A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers

Enrolling by invitation
2
332
Europe, Canada, US
ASTX727, cedazuridine + decitabine, INQOVI, DEC-C
Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
12/24
12/24
NCT04975919: Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting
2
20
US
Decitabine and Cedazuridine, ASTX727, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, Inqovi, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center
Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia
05/25
05/25
NCT05600894: Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Recruiting
2
132
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Decitabine and Cedazuridine, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inqovi, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myeloproliferative Neoplasm
08/25
08/25
NCT05960773: Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Recruiting
2
15
US
Decitabine/cedazuridine
National Cancer Institute (NCI)
Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
12/25
12/26
NCT04872543: A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

Recruiting
2
25
US
ASTX727
Memorial Sloan Kettering Cancer Center, Astex Pharmaceuticals, Inc.
Malignant Peripheral Nerve Sheath Tumors (MPNST)
04/26
04/26
NCT05799079: Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

Recruiting
2
51
US
Venetoclax, Decitabine, Cedazuridine, Bone Marrow Aspiration and Biopsy, Biospecimen Collection
Sanjay Mohan, National Comprehensive Cancer Network, Taiho Oncology, Inc.
Recurrent Acute Myeloid Leukemia
03/28
03/29
NCT05201066: Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Recruiting
2
70
Europe, US, RoW
decitabine, spartalizumab, PDR001, sabatolimab, MBG453, azacitidine, venetoclax, INQOVI (oral decitabine)
Novartis Pharmaceuticals
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
09/27
02/28
ACTRN12621001713886p: A dose determining trial to assess the recommended dose of ES-3000 and ASTX727 for patients with Myelodysplasia

Not yet recruiting
1/2
32
 
Australasian Leukaemia and Lymphoma Group , Escend Pharmaceuticals Inc
Myelodysplasia
 
 
ACTRN12622001302741: MDS05/D2 - Phase Ib/II study for treatment of Myelodysplasia (MDS) with SRA515 and ASTX727,

Not yet recruiting
1/2
86
 
Australasian Leukaemia and Lymphoma Group (ALLG), Australasian Leukaemia and Lymphoma Group (ALLG)
Myelodysplastic Syndrome (MDS), Acute Myeloid Leukaemia (AML)
 
 
ACTRN12621001713886: A dose determining trial to assess the recommended dose of ES-3000 and ASTX727 for patients with Myelodysplasia

Recruiting
1/2
32
 
Australasian Leukaemia and Lymphoma Group , Escend Pharmaceuticals Inc
Myelodysplasia
 
 
2022-001076-34: The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes ABNL-MARRO 001: Un estudio de fase I/II de combinaciones de compuestos con diana mieloide activa en síndromes mixtos SMD/NMP del tejido conjuntivo

Not yet recruiting
1/2
117
Europe
ASTX727, Itacitinib, Tablet
Theradex (Europe) Ltd., Vanderbilt University Medical Center, Incyte Corporation, Astex Pharmaceuticals
Myelodysplastic syndrome/Myeloproliferative Neoplasm Overlap Syndromes Síndromes de superposición mielodisplasia/neoplasia mieloproliferativa, Myelodysplastic syndrome/Myeloproliferative Neoplasm Overlap Syndromes Síndromes de superposición mielodisplasia/neoplasia mieloproliferativa, Diseases [C] - Cancer [C04]
 
 
NCT05148234: BMS-986253 in Myelodysplastic Syndromes

Terminated
1/2
2
US
Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253, Human Humax (HuMax)-interleukin 8 (IL-8) (BMS-986253), Bone Marrow Biopsy, Bone Marrow Aspiration, ECG, Electrocardiogram
National Cancer Institute (NCI)
Myelodysplastic Syndromes
02/23
07/23
NCT03019003: Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Active, not recruiting
1/2
13
US
Oral Decitabine, ASTX 727, Durvalumab, MEDI4736
Massachusetts General Hospital, AstraZeneca, Astex Pharmaceuticals, Inc.
Head and Neck Cancer
01/25
01/25
NCT05089370: Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

Recruiting
1/2
30
US
Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab
University of Colorado, Denver, National Comprehensive Cancer Network, Taiho Oncology, Inc.
Malignant Melanoma
07/25
07/26
NCT06284460: Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Not yet recruiting
1/2
36
US
ASTX029, ASTX727, Inqovi
M.D. Anderson Cancer Center
Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm, Myeloproliferative Neoplasm
12/25
12/27
ABNL-MARRO, NCT04061421: Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes

Recruiting
1/2
105
US
ASTX727, Fixed dose combination of cedazuridine (100mg) + oral decitabine (35mg), Itacitinib, INCB039110
Michael Savona, Incyte Corporation, Theradex, Astex Pharmaceuticals, Inc.
MDS/MPN
08/24
08/25
NCI-2021-02246, NCT04817241: Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

Active, not recruiting
1/2
55
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin, Daunomycin, Daunorrubicina, DNR, Leukaemomycin C, Rubidomycin, Rubomycin C, Decitabine and Cedazuridine, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inqovi, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia
08/24
08/24
KCP-8602-801, NCT02649790: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Checkmark From trial for myelodysplastic syndrome at ASH 2019
Dec 2019 - Dec 2019: From trial for myelodysplastic syndrome at ASH 2019
Active, not recruiting
1/2
277
Europe, Canada, US, RoW
KPT-8602, Eltanexor, ASTX727, Dexamethasone
Karyopharm Therapeutics Inc
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
08/24
12/24
NCI-2021-00893, NCT04774393: Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
84
US
Decitabine and Cedazuridine, ASTX727, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, Inqovi, Enasidenib, AG-221, CC-90007 Free Base, Ivosidenib, AG-120, Tibsovo, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
11/24
11/24
ASTX727-03, NCT03502668 / 2019-003281-40: Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Active, not recruiting
1/2
160
Europe, Canada, US
ASTX727 LD, oral decitabine (LD) + cedazuridine (E7727), ASTX727 SD, oral decitabine (SD) + cedazuridine (E7727)
Astex Pharmaceuticals, Inc.
Myelodysplastic Syndromes
12/24
12/24
SAVE, NCT05360160: A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia

Recruiting
1/2
43
US
SNDX-5613, Venetoclax, ASTX727
M.D. Anderson Cancer Center, Astex Pharmaceuticals, Inc., Syndax Pharmaceuticals
Acute Myeloid Leukemia
12/24
12/24
NCT04657081: Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

Active, not recruiting
1/2
188
Europe, Canada, US
Decitabine and Cedazuridine (ASTX727), INQOVI, Venetoclax, Venclexta
Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia
12/24
12/25
NCI-2021-06095, NCT05010122: ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recruiting
1/2
42
US
Decitabine and Cedazuridine, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inqovi, Gilteritinib, ASP-2215, ASP2215, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
01/25
01/25
ASTX660-03, NCT05403450: A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Active, not recruiting
1/2
132
Europe, US, RoW
Tolinapant, ASTX660, Decitabine + Cedazuridine, ASTX727
Astex Pharmaceuticals, Inc.
Relapsed/Refractory Peripheral T-cell Lymphoma
12/25
12/26
NCT06091267: PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Recruiting
1/2
72
RoW
IV Decitabine, Decitabine and cedazuridine, only Decitabine and cedazuridine
Otsuka Beijing Research Institute
Myelodysplastic Syndromes
12/25
06/26
NCT04655755: Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recruiting
1/2
52
US
Decitabine and Cedazuridine, ASTX727, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, Inqovi, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, Astex Pharmaceuticals, Inc., Genentech, Inc.
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
07/26
07/26
NCT05918055: Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Recruiting
1/2
80
US
KPT-8602, Inqovi
National Cancer Institute (NCI)
Myelodysplastic Syndromes
04/27
07/27
NCT06113289: A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia

Suspended
1/2
42
US
ASTX727, Inqovi, ASTX029-01
M.D. Anderson Cancer Center
Acute Myeloid Leukemia
05/27
05/29
NCT04742634: Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
126
US
DEC-C, decitabine + cedazuridine, ASTX727, INQOVI®, MyeloSeq-HD
Washington University School of Medicine, Taiho Oncology, Inc.
Myelodysplastic Syndromes
11/33
11/33

Download Options